Australian Workshops on Patients' Perspectives on Hemodialysis and Incremental Start.

hemodialysis incremental dialysis patient perspectives patient-centered care quality of life residual kidney function

Journal

Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 03 09 2022
revised: 25 10 2022
accepted: 22 11 2022
entrez: 20 3 2023
pubmed: 21 3 2023
medline: 21 3 2023
Statut: epublish

Résumé

Most patients with kidney failure commence and continue hemodialysis (HD) thrice weekly. Incremental initiation (defined as HD less than thrice weekly) is increasingly considered to be safe and less burdensome, but little is known about patients' perspectives. We aimed to describe patients' priorities and concerns regarding incremental HD. Patients currently, previously, or soon to be receiving HD in Australia participated in two 90-minute online workshops to discuss views about HD focusing on incremental start and priorities for trial outcomes. Transcripts were analyzed using thematic analysis. Outcomes were ranked on the basis of the sum of participants' priority scores (i.e., single allocation of 3 points for most important, 2 for second, and 1 for third most important outcome). All 26 participants (1 caregiver and 25 patients) preferred an incremental HD approach. The top prioritized outcomes were quality of life (QOL) (56 points), residual kidney function (RKF) (27 points), and mortality (16 points). The following 4 themes underpinning outcome priorities, experience, and safety concerns were identified: (i) unpreparedness and pressure to adapt, (ii) disruption to daily living, (iii) threats to safety, and (iv) hope and future planning. Patients with kidney failure preferred an incremental start to HD to minimize disruption to daily living and reduce the negative impacts on their education, ability to work, and family life. QOL was the most critically important outcome, followed by RKF and survival.

Identifiants

DOI: 10.1016/j.ekir.2022.11.012 PMID: 36938090 PMC: PMC10014336
pubmed: 36938090
doi: 10.1016/j.ekir.2022.11.012
pii: S2468-0249(22)01873-3
pmc: PMC10014336
doi:

Types de publication

Journal Article

Langues

eng

Pagination

478-488

Informations de copyright

© 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology.

Références

Nephrology (Carlton). 2009 Feb;14(1):59-64
pubmed: 19019171
Am J Nephrol. 2014;40(2):140-50
pubmed: 25171342
Lancet. 2014 Jan 11;383(9912):156-65
pubmed: 24411644
Am J Kidney Dis. 1997 Apr;29(4):584-92
pubmed: 9100049
Am J Kidney Dis. 2015 May;65(5):674-83
pubmed: 25582284
BMC Nephrol. 2022 Jul 23;23(1):263
pubmed: 35870885
Nephrol Dial Transplant. 2013 Nov;28(11):2815-23
pubmed: 23901048
Kidney Int. 2016 Nov;90(5):1071-1079
pubmed: 27528548
Am J Kidney Dis. 2014 Aug;64(2):181-6
pubmed: 24840669
Nephrology (Carlton). 2019 Nov;24(11):1172-1178
pubmed: 30632257
Am J Kidney Dis. 2016 Sep;68(3):444-54
pubmed: 26968042
Nephrol Dial Transplant. 2014 Sep;29(9):1770-7
pubmed: 24322579
Nephrol Dial Transplant. 2015 Oct;30(10):1639-48
pubmed: 26038351
Am J Kidney Dis. 2017 Oct;70(4):464-475
pubmed: 28238554
Am J Kidney Dis. 2016 Aug;68(2):256-265
pubmed: 26867814
Nephrology (Carlton). 2019 Apr;24(4):438-444
pubmed: 29532551
Nephrol Dial Transplant. 2009 Aug;24(8):2502-10
pubmed: 19240122
Nephrol Dial Transplant. 2017 Feb 1;32(2):355-363
pubmed: 28186541
Health Psychol Behav Med. 2021 Apr 30;9(1):380-397
pubmed: 34104566
Am J Kidney Dis. 2017 Jan;69(1):97-107
pubmed: 27497527
Nephrol Dial Transplant. 2016 Jan;31(1):133-41
pubmed: 26346314
Can J Kidney Health Dis. 2015 Oct 01;2:35
pubmed: 26430515
Kidney Int Suppl (2011). 2018 Feb;8(2):64-73
pubmed: 30675440
Kidney Int. 2022 Mar;101(3):615-625
pubmed: 34418414
Nephrol Dial Transplant. 2022 Nov 23;37(12):2514-2521
pubmed: 35731591
J Nephrol. 2019 Oct;32(5):823-836
pubmed: 30604150
Nefrologia. 2013;33(5):640-9
pubmed: 24089155
Am J Kidney Dis. 2022 Aug;80(2):227-240.e1
pubmed: 34933066
Kidney Int Rep. 2022 Feb 19;7(5):1049-1061
pubmed: 35571001
Blood Purif. 2014;38(3-4):253-62
pubmed: 25573488
Kidney Int Rep. 2019 Dec 06;5(2):135-148
pubmed: 32043027
Nephrol Dial Transplant. 2019 Nov 1;34(11):1806-1811
pubmed: 30805639
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
Perit Dial Int. 2020 May;40(3):320-326
pubmed: 32063212
Am J Nephrol. 1999;19(6):625-33
pubmed: 10592355
Nephrol Dial Transplant. 2019 Jun 1;34(6):1017-1025
pubmed: 30357360

Auteurs

Katharine Hegerty (K)

Department of Nephrology, Princess Alexandra Hospital, Queensland, Australia.
The University of Queensland, Brisbane, Queensland, Australia.

Allison Jaure (A)

The University of Sydney, New South Wales, Australia.
Center for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia.

Nicole Scholes-Robertson (N)

The University of Sydney, New South Wales, Australia.
Center for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia.

Kirsten Howard (K)

Menzies Center for Health Policy and Economics, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.

Angela Ju (A)

The University of Sydney, New South Wales, Australia.

Nicole Evangelidis (N)

The University of Sydney, New South Wales, Australia.
Center for Kidney Research, The Children's Hospital at Westmead, New South Wales, Australia.

Martin Wolley (M)

Royal Brisbane and Women's Hospital, Queensland, Australia.

Amanda Baumgart (A)

The University of Sydney, New South Wales, Australia.

David W Johnson (DW)

Department of Nephrology, Princess Alexandra Hospital, Queensland, Australia.
The University of Queensland, Brisbane, Queensland, Australia.
Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.
Translational Research Institute, Brisbane, Queensland, Australia.

Carmel M Hawley (CM)

Department of Nephrology, Princess Alexandra Hospital, Queensland, Australia.
The University of Queensland, Brisbane, Queensland, Australia.
Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.

Donna Reidlinger (D)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.

Laura Hickey (L)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.

Alyssa Welch (A)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.

Yeoungjee Cho (Y)

Department of Nephrology, Princess Alexandra Hospital, Queensland, Australia.
The University of Queensland, Brisbane, Queensland, Australia.
Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.

Peter G Kerr (PG)

Department of Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia.

Matthew A Roberts (MA)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.
Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.

Jenny I Shen (JI)

Division of Nephrology and Hypertension, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.

Jonathan Craig (J)

College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.

Rathika Krishnasamy (R)

The University of Queensland, Brisbane, Queensland, Australia.
Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.
Department of Nephrology, Sunshine Coast University Hospital, Queensland, Australia.

Andrea K Viecelli (AK)

Department of Nephrology, Princess Alexandra Hospital, Queensland, Australia.
The University of Queensland, Brisbane, Queensland, Australia.
Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.

Classifications MeSH